Published in Int J Mass Spectrom on January 01, 2007
Translation from the 5' untranslated region shapes the integrated stress response. Science (2016) 2.31
Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. Vaccine (2009) 0.96
HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands. Immunogenetics (2010) 0.81
A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol (2016) 0.77
Decoding sORF translation - from small proteins to gene regulation. RNA Biol (2016) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 13.90
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science (1992) 8.68
TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44
The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol (2005) 7.40
Lysosomal glycosphingolipid recognition by NKT cells. Science (2004) 7.31
Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature (1990) 6.23
Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science (1992) 5.99
Sequence analysis of peptides bound to MHC class II molecules. Nature (1991) 5.99
Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci (2003) 5.94
Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature (1995) 5.04
CD1-restricted T cell recognition of microbial lipoglycan antigens. Science (1995) 5.03
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med (1993) 4.99
Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity (1996) 4.68
Mechanisms of MHC class I--restricted antigen processing. Annu Rev Immunol (1998) 4.54
HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature (1992) 4.53
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (1994) 3.96
Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature (1992) 3.85
Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol (2005) 3.82
Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A (2003) 3.75
HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell (1995) 3.64
Murine CD1d-restricted T cell recognition of cellular lipids. Immunity (2000) 3.57
Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature (1995) 3.40
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
Costimulation and endogenous MHC ligands contribute to T cell recognition. Nat Immunol (2001) 3.24
Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med (1998) 3.03
Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev (2005) 2.96
Mining genomes: correlating tandem mass spectra of modified and unmodified peptides to sequences in nucleotide databases. Anal Chem (1995) 2.86
Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med (1994) 2.81
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med (1999) 2.77
Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science (1998) 2.76
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol (1998) 2.68
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol (2003) 2.67
T cell activation by lipopeptide antigens. Science (2004) 2.59
Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science (1995) 2.55
HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature (1992) 2.54
Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci U S A (2004) 2.49
An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature (1994) 2.41
Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci (2005) 2.32
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med (1996) 2.30
Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med (2001) 2.27
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A (1996) 2.24
A role for N-glycanase in the cytosolic turnover of glycoproteins. EMBO J (2003) 2.18
Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol (1995) 2.12
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science (1998) 2.11
DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity (1995) 2.10
HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol (1998) 2.09
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med (1997) 2.00
Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen. Cell (1994) 1.92
Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol (1995) 1.91
Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science (1995) 1.87
Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J Immunol (1993) 1.84
Immunodominant and subdominant CTL responses to Listeria monocytogenes infection. J Immunol (1997) 1.83
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res (2001) 1.79
The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity (1997) 1.78
Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell (1996) 1.76
Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J (1996) 1.74
Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunol Rev (2005) 1.74
TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol (1998) 1.70
Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med (1999) 1.70
The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J Biol Chem (1995) 1.70
Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science (1992) 1.63
The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med (2001) 1.53
In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur J Immunol (2001) 1.48
Trimming of antigenic peptides in an early secretory compartment. J Exp Med (1994) 1.47
Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J Exp Med (2000) 1.45
Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature (1990) 1.45
MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. J Immunol (1997) 1.44
PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics (2001) 1.44
The law of mass action governs antigen-stimulated cytolytic activity of CD8+ cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1995) 1.43
The CD1 family of lipid antigen-presenting molecules. Immunol Today (1998) 1.42
A Listeria monocytogenes pentapeptide is presented to cytolytic T lymphocytes by the H2-M3 MHC class Ib molecule. Immunity (1996) 1.41
Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire. J Biol Chem (2003) 1.38
Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol (1999) 1.38
Identification of proteins that interact with mammalian peptide:N-glycanase and implicate this hydrolase in the proteasome-dependent pathway for protein degradation. Proc Natl Acad Sci U S A (2001) 1.34
Characteristics of endogenous peptides eluted from the class I MHC molecule HLA-B7 determined by mass spectrometry and computer modeling. J Immunol (1993) 1.33
Presentation of antigens by MHC class II molecules: getting the most out of them. Mol Immunol (2001) 1.33
The turnover kinetics of major histocompatibility complex peptides of human cancer cells. Mol Cell Proteomics (2005) 1.33
MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics (2003) 1.31
Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells. Nature (1993) 1.30
Minimal requirements for peptide mediated activation of CD8+ CTL. Mol Immunol (1994) 1.28
All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev (2005) 1.27
Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med (2001) 1.26
Three-dimensional structure of a peptide extending from one end of a class I MHC binding site. Nature (1994) 1.26
Post-translational modifications of naturally processed MHC-binding epitopes. Curr Opin Immunol (2005) 1.24
Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J Immunol (2000) 1.23
Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol (1998) 1.22
Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer (2001) 1.20
HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res (1994) 1.20
Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J Immunol (1994) 1.19
Tapasin is a facilitator, not an editor, of class I MHC peptide binding. J Immunol (2003) 1.19
The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood (2003) 1.18
The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood (2006) 1.17
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med (2006) 1.17
Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets. J Immunol (2002) 1.16
The human 26 S and 20 S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate. J Biol Chem (2000) 1.15